Invega Trinza

Invega Trinza

paliperidone

Manufacturer:

Johnson & Johnson
Concise Prescribing Info
Contents
Paliperidone palmitate
Indications/Uses
A 3-mth inj for the maintenance treatment of schizophrenia in adult patients who have been adequately treated w/ 1-mth paliperidone palmitate inj for at least 4 mth.
Dosage/Direction for Use
IM Conversion from paliperidone palmitate 1-mth inj to Invega Trinza: If last 1-mth inj dose is 100 mg, initiate Invega Trinza at 350 mg. If last 1-mth inj dose is 150 mg, initiate Invega Trinza at 525 mg. Administer every 3 mth following initial dose. Dose may be adjusted in increments w/in the range of 175-525 mg based on individual patient tolerability/efficacy. Re-initiation regimen after missing >4 up to 9 mth Invega Trinza: If last Invega Trinza dose is 350 mg, administer paliperidone palmitate 1-mth inj 100 mg on days 1 & 8, then give Invega Trinza 350 mg 1 mth after day 8. If last Invega Trinza dose is 525 mg, administer paliperidone palmitate 1-mth inj 100 mg on days 1 & 8, then give Invega Trinza 525 mg 1 mth after day 8. Conversion from Invega Trinza to paliperidone palmitate 1-mth inj: If last Invega Trinza dose is 350 mg, administer 1-mth paliperidone palmitate 100 mg. If last Invega Trinza dose is 525 mg, administer 1-mth paliperidone palmitate 150 mg. Switching from Invega Trinza to oral paliperidone XR tab: If last Invega Trinza dose is 350 mg, give the following oral paliperidone XR tab daily dose: ≥3 mth - ≤18 wk since last Invega Trinza dose: 3 mg, >18 wk - ≤24 wk since last Invega Trinza dose: 6 mg, >24 wk since last Invega Trinza dose: 9 mg. If last Invega Trinza dose is 525 mg, give the following oral paliperidone XR tab daily dose: ≥3 mth - ≤18 wk since last Invega Trinza dose: 6 mg, >18 wk - ≤24 wk since last Invega Trinza dose: 9 mg, >24 wk since last Invega Trinza dose: 12 mg.
Contraindications
Hypersensitivity to paliperidone, risperidone.
Special Precautions
Do not administer intravascularly or SC; divided inj. Not approved for the treatment of patients w/ dementia-related psychosis. Discontinue if patient develops signs or symptoms of neuroleptic malignant syndrome; tardive dyskinesia; hypersensitivity reactions; severe neutropenia. Avoid combination w/ drugs known to prolong QTc eg, quinidine, procainamide, amiodarone, sotalol, antiarrhythmics, chlorpromazine, thioridazine, gatifloxacin, moxifloxacin. Patients w/ congenital long QT syndrome, history of cardiac arrhythmias; known CV or cerebrovascular disease, conditions that predispose patient to hypotension; history of seizures or other conditions that potentially lower the seizure threshold; history of clinically significant low WBC count or a drug-induced leukopenia/neutropenia. Monitor for symptoms of hyperglycemia & DM; wt gain. Venous thromboembolism; Parkinson's disease & dementia w/ lewy bodies; priapism. May disrupt body's ability to reduce core body temp. Antiemetic effect may mask signs & symptoms of overdosage w/ certain drugs or of conditions eg, intestinal obstruction, Reye's syndrome & brain tumor. Intraoperative floppy iris syndrome. May impair ability to drive & use machines. Hepatic & moderate or severe renal impairment. Pregnancy & lactation. Childn & adolescents <18 yr. Elderly.
Adverse Reactions
Upper resp tract infection, UTI, nasopharyngitis; hyperglycemia, hyperinsulinemia, increased/decreased wt; anxiety, schizophrenia, insomnia, depression; akathisia, dyskinesia, dystonia, headache, parkinsonism, somnolence; tachycardia; orthostatic hypotension, HTN; nausea, vomiting, diarrhoea; amenorrhea, galactorrhea; inj site reaction/induration/pain, fatigue.
Drug Interactions
Drugs known to prolong QT interval. Concomitant use w/ other centrally acting drugs & alcohol. May antagonize the effect of levodopa & other dopamine agonists. Additive effect w/ drugs inducing orthostatic hypotension. Co-administration w/ carbamazepine; risperidone or oral paliperidone.
MIMS Class
ATC Classification
N05AX13 - paliperidone ; Belongs to the class of other antipsychotics.
Presentation/Packing
Form
Invega Trinza PR susp for inj 350 mg/1.75 mL
Packing/Price
1's
Form
Invega Trinza PR susp for inj 525 mg/2.625 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in